Louise Rodino-Klapac
2021
Compensation breakdown
| Non-Equity Incentive Plan | $360,000 |
|---|---|
| Option Awards | $2,959,290 |
| Salary | $555,577 |
| Stock Awards | $4,626,650 |
| Other | $14,106 |
| Total | $8,515,623 |
Rodino-Klapac received $4.6M in stock awards, accounting for 54% of the total pay in 2021.
Rodino-Klapac also received $360K in non-equity incentive plan, $3M in option awards, $555.6K in salary and $14.1K in other compensation.
Rankings
In 2021, Louise Rodino-Klapac's compensation ranked 1,326th out of 12,415 executives tracked by ExecPay. In other words, Rodino-Klapac earned more than 89.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,326 out of 12,415 | 89th |
Division Manufacturing | 474 out of 5,505 | 91st |
Major group Chemicals And Allied Products | 173 out of 2,375 | 93rd |
Industry group Drugs | 145 out of 2,096 | 93rd |
Industry Pharmaceutical Preparations | 95 out of 1,546 | 94th |
Pay ratio
| Louise Rodino-Klapac's Pay | $8,515,623 |
|---|---|
| Median Employee's Pay | $271,908 |
| Pay Ratio | 31to 1 |
In 2021, the annual total compensation of Louise Rodino-Klapac was $8,515,623.
The annual total compensation of the median employee at Sarepta Therapeutics was $271,908.
The ratio of Louise Rodino-Klapac's pay to the pay of median employee was therefore 31 to one.
Rodino-Klapac's colleagues
We found four more compensation records of executives who worked with Louise Rodino-Klapac at Sarepta Therapeutics in 2021.